CASTLE BIOSCIENCES, INC. Payments to Acquire Debt Securities, Available-for-sale
CASTLE BIOSCIENCES, INC. (CSTL) reported Payments to Acquire Debt Securities, Available-for-sale of $109.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $54.49M, a 22.71% increase year-over-year.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $55.14M, a 13.84% increase year-over-year.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $37.41M, a 20.95% decline year-over-year.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $58.47M, a 29.32% increase year-over-year.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $188.71M, a 8.27% decline from fiscal 2024.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $205.73M, a 8.81% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $189.07M, a 40.38% increase from fiscal 2022.
- CASTLE BIOSCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $134.69M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $109.62M 10-Q · filed 2026-07-30 | $147.03M derived: sum of 3 quarters · filed 2026-07-30 | $205.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $55.14M 10-Q · filed 2026-05-06 | $92.54M derived: sum of 2 quarters · filed 2026-05-06 | $151.02M derived: sum of 3 quarters · filed 2026-05-06 | $195.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $37.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $95.88M derived: sum of 2 quarters · filed 2026-02-26 | $140.28M derived: sum of 3 quarters · filed 2026-07-30 | $188.71M 10-K · filed 2026-02-26 |
| 2025-09-30 | $58.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $102.88M derived: sum of 2 quarters · filed 2026-07-30 | $151.31M 10-Q · filed 2025-11-03 | $198.63M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $44.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $92.83M 10-Q · filed 2026-07-30 | $140.15M derived: sum of 3 quarters · filed 2026-07-30 | $185.37M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $48.43M 10-Q · filed 2026-05-06 | $95.75M derived: sum of 2 quarters · filed 2026-05-06 | $140.97M derived: sum of 3 quarters · filed 2026-05-06 | $193.41M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $47.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $92.53M derived: sum of 2 quarters · filed 2026-02-26 | $144.97M derived: sum of 3 quarters · filed 2026-02-26 | $205.73M 10-K · filed 2026-02-26 |
| 2024-09-30 | $45.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $97.66M derived: sum of 2 quarters · filed 2025-11-03 | $158.41M 10-Q · filed 2025-11-03 | $210.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $52.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $113.19M 10-Q · filed 2025-08-04 | $165.58M derived: sum of 3 quarters · filed 2026-02-26 | $215.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $60.75M 10-Q · filed 2025-05-05 | $113.14M derived: sum of 2 quarters · filed 2026-02-26 | $163.39M derived: sum of 3 quarters · filed 2026-02-26 | $219.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $52.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $102.64M derived: sum of 2 quarters · filed 2026-02-26 | $158.99M derived: sum of 3 quarters · filed 2026-02-26 | $189.07M 10-K · filed 2026-02-26 |
| 2023-09-30 | $50.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $106.61M derived: sum of 2 quarters · filed 2024-11-04 | $136.69M 10-Q · filed 2024-11-04 | $139.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $56.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $86.44M 10-Q · filed 2024-08-05 | $89.32M derived: sum of 3 quarters · filed 2025-02-27 | $221.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $30.08M 10-Q · filed 2024-05-02 | $32.96M derived: sum of 2 quarters · filed 2025-02-27 | $164.77M derived: sum of 3 quarters · filed 2025-02-27 | $164.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $134.69M derived: sum of 2 quarters · filed 2025-02-27 | $134.69M derived: sum of 3 quarters · filed 2025-02-27 | $134.69M 10-K · filed 2025-02-27 |
| 2022-09-30 | $131.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $131.81M derived: sum of 2 quarters · filed 2023-11-02 | $131.81M 10-Q · filed 2023-11-02 | $131.81M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2023-08-02 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2023-05-03 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |